研究单位：[1]Chia Tai Tianqing Pharmaceutical Group Co., Ltd.[2]Cancer Hospital Chinese Academy of Medical Sciences,Beijing,Beijing,China,100021[3]Jiangmen Central Hospital,Jiangmen,Guangdong,China,529000[4]Affiliated Hospital of Hebei University,Baoding,Hebei,China,071002[5]Harbin Medical University Cancer Hospital,Harbin,Heilongjiang,China,150081[6]The First Affiliated Hospital of Henan University of Science and Technology,Luoyang,Henan,China,471003[7]Inner Mongolia Baotou Steel Hospital,Baotou,Neimenggu,China,014010[8]Shandong First Medical University Affiliated Cancer Hospital,Jinan,Shandong,China,250117[9]Tianjin Medical University Cancer Institute and Hospital,Tianjin,Tianjin,China,300040[10]Tianjin Medical University General Hospital,Tianjin,Tianjin,China,300070[11]The Second Hospital of Tianjin Medical University,Tianjin,Tianjin,China,300211[12]Tianjin Chest Hospital,Tianjin,Tianjin,China,300222[13]Tianjin Fifth Central Hospital,Tianjin,Tianjin,China,300450
研究目的：
This is a Phase Ib clinical trial to evaluate the safety and efficacy of TQB2450 injection combined with AL2846 capsules in patients with advanced solid tumors.
